Clinical trial
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded…
NCT00436618 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00436618 |
|---|---|
| Title | Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment |
| Official title | Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Lymphoproliferative Disorder |
| Intervention type | Drug |
| Interventions | Everolimus |
| Enrollment | 277 |
| Start date | Aug 1, 2005 |
| Primary completion | Dec 1, 2010 |
| Completion | Oct 9, 2019 |
| First posted | Feb 19, 2007 |
| Last update posted | Oct 22, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: